Similar Articles
941 Importance of SALL4 in the development and prognosis of hepatocellular carcinoma
942 Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play
943 Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma
944 Does autologous blood transfusion during liver transplantation for hepatocellular carcinoma increase risk of recurrence?
945 Hepatocellular carcinoma: Where are we?
946 Blood DNA methylation markers in prospectively identified hepatocellular carcinoma cases and controls from Taiwan
947 Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?
948 Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art
949 Hepatocellular carcinoma and hepatitis B surface protein
950 Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA